AZD9742 single and multiple ascending dose study in healthy male and female Japanese subjects
Study identifier:D2690C00003
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase I, Single center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Intravenous AZD9742 in Healthy Male and Female Japanese Subjects
Medical condition
Healthy
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD9742, Placebo
Sex
All
Actual Enrollment
35
Study type
Interventional
Age
23 Years - 45 Years
Date
Study Start Date: 01 Apr 2010
Primary Completion Date: 01 Jul 2010
Study Completion Date: 01 Jul 2010
Study design
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 Dose level A, B, C and optional Dose level D and E: single administration and one to three times daily for 6 days (Japanese n=8) | Drug: AZD9742 IV Formulation |
| Placebo Comparator: 2 placebo given (2 subjects in each dose group) | Drug: Placebo IV Formulation |
Contacts
Investigators
Principal Investigator
Mark Yen
California Clinical Trials
